Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...
At the heart of Eli Lilly's recent success and future prospects lies its formidable GLP-1 portfolio, headlined by Mounjaro (tirzepatide) and Zepbound. These drugs have shown remarkable efficacy in ...
Hosted on MSN15d
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challengesAt the heart of Eli Lilly's recent success and future prospects lies its formidable GLP-1 portfolio, headlined by Mounjaro (tirzepatide) and Zepbound. These drugs have shown remarkable efficacy in ...
What to Expect From Blockbuster GLP-1 Treatments Much of Eli Lilly's momentum in recent quarters has been due to Mounjaro and Zepbound. However, in January 2025, the company updated its 2024 ...
At the heart of Eli Lilly's growth story is its robust portfolio of GLP-1 drugs. Mounjaro and Zepbound have shown impressive prescription growth trends, with Mounjaro experiencing a 21.6% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback